All In Biotech

BLA 103951 · Amgen

Aranesp

Darbepoetin Alfa · Subcutaneous, Intravenous · Erythropoiesis-stimulating Agent

Novel

Last checked: Nov 20, 2026Latest source record: Apr 30, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Sep 17, 2001

Approved uses

8

Original approval plus efficacy supplements

Registered trials

216

100 Phase 3, 10 recruiting

FAERS reports

54,075

48,342 serious, 20,052 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE Chronic Kidney Disease: In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis -stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL [ see Warnings and Precautions ( 5.1 )] . No trial has identified a hemoglobin target level, Aranesp dose, or dosing strategy that does not increase these risks [see Dosage and Administration ( 2.2 )] . Use the lowest Aranesp dose sufficient to reduce the need for red blood cell (RBC) transfusions [see Warnings and Precautions ( 5.1 )] . Cancer: ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with...

What it is approved for

From the label in effect Jul 7, 2026.

Aranesp is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia due to: Chronic Kidney Disease (CKD) in patients on dialysis and patients not on dialysis ( 1.1 ). The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.2 ). Limitations of Use Aranesp has not been shown to improve quality of life, fatigue, or patient well-being ( 1.3 ). Aranesp is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.3 ). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.3 ). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.3 ). As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.3 ). 1.1 Anemia Due to Chronic Kidney Disease Aranesp is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis. 1.2 Anemia Due to Chemotherapy in Patients with Cancer Aranesp is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. 1.3 Limitations of Use Aranesp has not been shown to improve quality of life, fatigue, or patient well-being. Aranesp is not indicated for use: • In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy. • In...

Mechanism: Aranesp stimulates erythropoiesis by the same mechanism as endogenous erythropoietin.

Therapeutic areas: Hematology and blood cancers

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

10 products under this application
  • ARANESP · DARBEPOETIN ALFA 100UG/ML · VIAL, SUBCUTANEOUS · Prescription
  • ARANESP · DARBEPOETIN ALFA 40UG/ML · VIAL, SUBCUTANEOUS · Prescription
  • ARANESP · DARBEPOETIN ALFA 200UG/ML · VIAL, INTRAVENOUS · Prescription
  • ARANESP · DARBEPOETIN ALFA 60UG/ML · VIAL, INTRAVENOUS · Prescription
  • ARANESP · DARBEPOETIN ALFA 25UG/ML · VIAL, INTRAVENOUS · Prescription
  • ARANESP · DARBEPOETIN ALFA 60UG/ML · VIAL, SUBCUTANEOUS · Prescription
  • ARANESP · DARBEPOETIN ALFA 25UG/ML · VIAL, SUBCUTANEOUS · Prescription
  • ARANESP · DARBEPOETIN ALFA 100UG/ML · VIAL, INTRAVENOUS · Prescription
  • ARANESP · DARBEPOETIN ALFA 200UG/ML · VIAL, SUBCUTANEOUS · Prescription
  • ARANESP · DARBEPOETIN ALFA 40UG/ML · VIAL, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Darbepoetin Alfa" as an intervention, any sponsor and status, largest first.

All 216 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death16,296
  • hospitalisation6,211
  • off label use2,624
  • anaemia2,197
  • haemoglobin decreased1,664
  • product storage error1,623
  • pneumonia1,504
  • fatigue1,491
  • dyspnoea1,458
  • diarrhoea1,339
  • nausea1,309
  • fall1,218

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004499
2005637
2006935
2007935
2008860
2009914
2010935
20111,073
20121,680
20131,536
20145,752
20156,451
20166,847
20177,062
20184,413
20191,520
20201,681
20211,595
20221,610
20232,363
20241,996
20251,434
20261,347

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Aranesp (Darbepoetin Alfa In Polysorbat)

2024 spending

$62.5M

Beneficiaries

6,472

27,006 claims

Per beneficiary

$9,663

$2,556.45 per unit

View as table
YearSpending
2020$53,121,165
2021$50,716,091
2022$54,796,645
2023$59,909,953
2024$62,541,381

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 276 on PubMed

Sponsor: Amgen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.